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The muscanmc cholinergic antagonist 3-quinudidinyl ben-
zilate (QNB) binds avidly but reversibly to the muscarinic choliner-
gic receptor of mammalian brain and peripheral tissues. [3H]-QNB 
binding provides a simple, sensitive and specific assay for the mu-
scarinic cholinergic receptor binding. Inhibition of [3H]-QNB bind-
ing to homogenates of brain and guinea pig ileum by muscarinic 
drugs correlates with their pharmacologic potencies, while nico-
tinic agents and noncholinergic drugs have negligible affinity. The 
regional distribution of [3H]-QNB binding throughout rat and mon-
key brain parallels to a major extent other cholinergic markers, 
suggesting that the majority of cholinergic synapses in the brain 
are muscarinic. [3H]-QNB accumulation in various brain regions 
after intravenous injection provides a means of labelling the mu-
scarinic receptor in vivo. By labelling the receptor in vivo, auto-
radiographic studies under the light microscope have been per-
formed to visualize the muscarinic receptor. 
Neurotransmitter receptor sites may be operationally defined as the »re-
cognition« sites for the transmitter. A great deal of research effort has been 
directed in the past few years to studies of the nicotinic chol.inergic receptor, 
espedally in the electric organ of certain invertebrates1- 3• Most of these studies 
have made use of a specific and tightly binding neurotoxin derived from snake 
venom, whose interactions with the receptor are. almost irreversible. Some 
studies have employed equilibrium dialysis of purified receptor or tissue frag-
ments against radiolabelled cholinergic agonists. With techniques from investi-
gations of opiate receptor binding in animal bmin4, we identified 1the synaptic 
receptor for the neurotransmitter actions of glycine in mammalian brain by 
measuring the reversible binding of the glycine antagonist strychnine to syna1ptic 
membrane. fractions 5. Because most cholinergic synapses in the brain are thought 
to be musoarinic rather than nicotinic, we were interested in investigating 
muscarinic cholinergic receptor binding in the brain. Using [3H]-atropine, Paton 
and Rang6 first studied muscarinic receptor binding in the guinea pig ileum. 
Based on our experience wi1th the glycine receptor, we have examined musca-
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rinic receptor binding both in the brain and the guinea pig ileum by measuring 
interactions of tissue membrane fractions with a reversible musoarinic cho-
linergic antagonist, 3-quinuclidinyl benzilate (QNB)7,8. Other groups have 
studied the interaction of brain preparations with cholinergic agonists or alky-
lating a-gents derived from muscarinic agonists as well as .atropine-like 
agen ts6,!J-16 . 
The binding of [3H]-QNB to membrane preparations of brain and guinea 
pig ileum has provided a rapid, sensitive, simple and specific assay for the 
muscarinic cholinergic receptor and has enabled us to compare the properties 
of this receptor in the brain and in peripheral tissues17-19. By regional com-
parisons of the distribution of the muscarinic receptor with othe.r cholinergic 
markers, we have been able to assess the extent to which muscarinic synapses 
account for cholinergic function in the brain. The avid but reversible binding 
of (3H]-QNB has enabled us to label muscarinic receptors in the brain in vivo. 
By labelling muscarinic receptors in vivo with ['3H]-QNB, it has been posstble 
to perform autoradiographic studies to localize receptor binding in a detailed 
fashion and, hopefully, ultimately to map muscarirric cholinergic pathways 
in mammalian brain. 
Phmmacologic Specificity of the Muscarinic Receptor 
In initial studies, we were able to show that low concentrations of [3H]-QNB 
bind to brain homogenates in a fashion that can be almost completely inhi-
bited by unlabelled QNB or cholinergic muscarinic agonists such as oxotre-
morine. Under the standard binding conditions only about 50-70 c.p.m. of 
[3H]-QNB are entrapped by tissue in the presence of excess amounts of QNB 
or oxotremorine so that with low concentrations of [3H]-QNB (0 .1-0.6 nM) 
specific receptor binding is about 10 times nonspecific binding17• In various 
subcellular fractions, specific QNB binding is most abundant in crude mito-
chondrial fractions which are enriched in synaptosomes or pinched-off nerve 
endings17• 
Using whole rat brain homogenates, [3H]-QNB binding is saturable with 
half-maximal binding at about 0.4 nM. By contrast, nonspecific binding, in the 
presence of 0.01 µM unlabelled QNB or 100 µM oxotremorine, is not saturable 
and increases linearly with increasing [3H]-QNB. [3H]-QNB binding is inhibited 
by nonradioactive QNB with half-maximal displacement at about 0.4-0.5 nM 
nonradioactive QNB, essentially the same value for half-saturation obtained 
with [3H]-QNB. By contrast, the agonist oxotremorine has much less affinity 
for binding sites so that half-maximal inhibition requires about 0.7 µM oxo-
tremorine. These characteristics of [3H]-QNB binding, especially saturation and 
displacement by QNB and oxotremorine are closely similar in homogenates 
of the guinea pig ileum and in the brain19• 
The fact that QNB binding is saturiable at low concentrations and can be 
inhibited by a muscarinic agonist is by no means sufficient evidence to ensure 
that the binding involves the pharmacologically relevant muscarinic receptor. 
To ensure specificity, one must evaluate a wide range, of muscarinic drugs 
as well as numerous drugs which are not thought to interact with the musca-
rinic receptor. Ideally, one would like to correlate the molar affinity for binding 
sites with pharmacologic potency. Such correlations cannot be obtained in the 
brain. However, in the guinea pig ileum, one can measure in the same intestinal 
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strip the ability of drugs to inhibit [3H]-QNB binding and to alter the contria-
ctile properties of the muscle. Accordingly, we compared the ability of a 
wide range of muscarinic agonists and antagonists to inhibit [3H]-QNB binding 
in the brain and in the guinea pig ileum and examined the relati<onship of 
these values to those obtained for the influence of these drugs upon contria-
ction of the guinea pig ileum (Table I) . 
TABLE I. 
ReLative Potencies of Drugs in Reducing [3H]QNB Binding to Rat Brain Homogenates 
and to the LongitudinaL Muscle of the Guinea Pig 
Rat Brain I Guinea Pig I Biological Ref. Drugs IDso/M" Ileum Values (19) IDso/M" EDso/M" 
Antagonists 
3-Quinuclidinyl benzilate 4-5x10-10 2-3x10-10 5X 10-1,0 
Scopolamine 7-9x10-10 2-3X10-M 3X 10-10 . (6) 
Atropine 1-2x10-9 2-4x10-9 1x10-9 (6) 
Isopropamide l-2x10-9 6-7x10-9 (57) 
Diphenyldioxolane 1-2x10-s 3X 10-s 2x10-s 
Mixed agonists-antagonists 
Pilocarpine 7x10-6 7-9x10-1 1x10-6 (58, 59) 
DL-Diisopropyl-dioxolane 4x10-s 7x10-5 3X10-5 (60) 
D-Diisopropyl-dioxolane 2-3x10-s 3x10-s 4x10-s (60) 
L-Diisopropyl-dioxolane 7X10-s 8X 10-5 9x10-5 (60) 
Agonists 
Oxotremorine 5-sx10-1 5-8x10-1 
Arecoline 1-3x10-6 3-4X10c6 
Acetylcholiine0 2-4x10-6 2-4x10-a 4-6x10-s (58,61) 
Acetyl-~-methylcholine 3-5x10-a 2-3x10-a 5-6x10-s (58, 60) 
DL-Cis-methyl-dioxolane 7-9x10-a 6-8x10-6 2X10-s (60) 
D-Cis-metyl-dioxolane 2-3x10-5 3-4x10-5 2x10-1 (60) 
L-Cis metyl-dioxolane 7-9x10-6 2x10-s (60) 
No Effect at 10 1-iM: 
D-Acetyl-~-methylcholine, aspartic acid, gamma-aminobutyric acid, glutamic 
acid, proline, naloxone, methylphenidate, glycine, pempidine, levorphanol, dextror-
phan, purified cnrticotoxin and neurotoxin from the cobra (Naja Naja), hexametho-
nium, D-tubocurarine, mecamylamine, 1~.9-tetrahydrocannabinol, diazepam, napthyl-
-vinylpyridinium (NVP), chlordiazepoxide and angiotensin. 
a Concentration of drug which inhibited specific ('H]QNB binding by 500/o<. 
" Values listed are the EDso (concentrations for 50'/o of maximal response) obtained in pharma-
cological procedures using intact smooth muscle preparations. The smooth muscle used in 
references 57, 60, 61 and 59 was the longitudinal muscle of guinea pig ileum, while that used 
in reference 58 was the circular muscle of the rabbit stomach fundus. 
' Physostigmine (1 µM) was added to the incubation to prevent enzymatic (AChE) hydrolysis . 
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QNB itself is one of the most p()l1;ent muscarinic antagonists, causing 50°/o 
inhibition of [3H]-QNB binding at concentrations under 0.5 nM both in the 
brain and the guinea pig ileum. Other muscarinic antagonists such as scopo-
lamine, atropine, diphenyldioxolane and isopropamide are also very potent 
inhibitors of [3H]-QNB binding in brain and intestine and are potent antagonists 
of acetylcholine induced contractions of the muscle. The pharmacologic poten-
cies of the antagonists are similar to the concentrations of the agents which 
inhibit QNB binding 50%. Mixed agonist-antagonists, such as pilocarpine and 
di-isopropyl-dioxolane, also have similar biological and binding potencies. 
There are some marked discrepancies between biological potencies of 
agonists and their potencies as inhibitors of QNB binding. Agonists for which 
we have both biological and binding data are two to four orders of magnitude 
more potent in contracting intestinal strips than in reducing [3H]-QNB binding. 
For ~nstance, acetylcholine elicits 50°/o of maximal contraction at about 0.05 
~tM concentration (ED5 0 value) but requires about 3 ~tM concentration to lower 
[
3H]-QNB binding by 500/o. If the ED50 values correspond to the concentration 
of drug for half maximal receptor occupation, then there are major differences 
between biological and binding data. 
Some workers have postulated that the majority, as much as 900/o or 
more, of muscarinic receptors in the guinea pig intestine are »spare« receptors 
so tha·t occupation by a pure agonist such as acetylcholine of only a small 
proportion will elicit a maximal biologic response20• In this situation one may 
determine the extent of receptor occupation biologically by measuring the ED50 
of the agonist ·after »removing« all the spare receptors with an alkylating 
drug. In these exiperiments 500/o receiptor occupation appears to occur at 2-3 µM 
concentrations of acetylcholine and acetyl ~-methylcholine, similar to the 
concentrations for 50°/o inhibition of QNB binding. However, it is possible 
that the ability of alkylating drugs to reduce the potency of agonists without 
altering the maximal response does not result from destruction of spare 
receptors for the :agonist. According to this latter formulation, there are no 
spare muscartnic receptors in the guinea pig intestine. Instead, the biological 
ED50 values for an agonist correspond closely to the concentration required 
for 50°/o receptor occupation. In this case, the major discrepancies between 
binding and biological data require explanation. 
An allosteric model of receptor function is consistent with the dose 
correspondence between biologic and binding data for antagonists but not for 
agonists21 ,22• Neurotransmitter receptors are postulated to exist in intercon-
vertible »agonist« and »antagonist« conformations. Agonists have high and 
low affinities respectively for the agonist and antagonist receptor states while 
the reverse situation occurs for antagonists. Neurotransmission occurs only 
when an agent binds to the agonist conformation of the receptor and is as-
sociated with a change in binding to the receptor of a relevant ion, triggering 
a change in the ion's membrane conductance. We have obtained direct evidence 
for the existence of interconvertible agonist and antagonist states of the opiate 
and glycine receptors23- 28. Low concentrations of sodium selectively transform 
the opiate receptor into the antagonist form24,29. Chloride and other anions 
inhibit receptor binding of strychnine, the glycine antagonist, in proportion 
to their ability to mimic the synaptic actions of chloride at glycine synapses5• 
Conceivably such a model of receptor dynamics may apply to the musoarinic 
receptor. According to this formulation, QNB and other antagonists bind to 
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the antagonist conformation of the receptors, explaining the good agreement 
of biologic and binding data. Because pure agonists have much less affinity for 
the antagonist than for the agonist conformation of the receptor, they are 
much less potent in reducing QNB binding than in contracting intestinal strips, 
the latter reflecting their high affinity for the agonist form of the receptor. 
Mixed agonist-antagonists, with similar affinities for both agonist and antagonist 
receptor states, should inhibit QNB binding and contract intestinal strips with 
similar potencies, as is observed experimentally. 
As a check on specificity of QNB binding to muscarinic receptor, a wide 
range of nicotinic cholinergic agents as well as noncholinergic drugs have 
been examined for their ability to inhibit QNB binding. All of those agents 
have little effect at concentrations of 10 µM (Table I) . 
Regional Distribution of the Muscarinic Receptor 
Although neurophysiologic studies in general suggest that muscanmc 
cholinergic receptors account for a major portion of cholinergic synapses in 
mammalian brain, the identification of specific synapses as muscarinic or 
nicotinic has never been altogether clear. Musoarinic receptors seem to pre-
dominate in the caudate nucleus, putamen and cerebral cortex30- 32, while in 
the spinal cord, acetylcholine receptors of the Renshaw cells are nicotinic33- 35 . 
In several regions both nicotinic and muscarinic receptors appear to be present, 
according to neurophysiologic studies. In an effort to examine this question, 
we e,valuated the density of [3H]-QNB binding sites in numerous regions of the 
monkey brain and compared QNB binding with high affinity choline uptake, 
thought to label cholinergic nerve terminals selectively36- 38 , the activity of 
choline acetyltransferase, the acetylcholine synthesizing enzyme, and the 
activity of cholinesterase39 (Table II) . 
There are marked regional variations in QNB binding with at least a 
29-fold variation between the putamen, containing the highest density of 
binding sites and the optic chiasm, the lowest. The head and body of the 
caudate contain about the same amount of binding as the putamen, which in 
turn contains 6 times as much binding as the closely juxtaposed globus pal-
lidus. The six areas of the cerebral cortex examined contain similar amounts 
of QNB binding, about half the levels of the caudate and putamen. The 
amygdala and hippocampus possess about the same amount of binding as the 
cerebral cortex. In all three regions of the thalamus examined, binding is 
similar and levels are somewhat higher than in the hypothalamus. Within the 
midbrain, highest binding occurs in the superior colliculi, almost 1.5 times 
that of the inferior colliculi and 3 times binding in raphe area. Binding of 
QNB in the pons .is only about half that of the superior colliculi but double 
that of the m edulla oblongata. The lowest QNB binding in the <brain stem 
occurs in the inferior olivary nucleus, less than half that of the medulla 
oblong a ta. 
QNB binding in the cervical spinal cord is the same as in the inferior 
olivary nucleus and similar to values in the optic chiasm, the lowest area of 
the brain. Interestingly, although QNB binding is low in areas containing 
exclusively white matter such as the corpus callosum, corona radiata and 
cerebral peduncles, levels are definitely demonstrable in these regions and 
are comparable to binding in the cerebellar cortex. Conceivably, in white 
matter areas wh ich contain axons but no cells or nerve terminals, QNB 
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TABLE II. 
Regional Distribution o.f Specific [3H]QNB Binding, [3H]Choline Uptake, Choline 
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4.4 ± 0.6 
3.28± 0.6 
6.47 ± 1.1 
7.95 ± 1.3 
6.35± 0.5 
18.6 ± 5.2 
1.4 ± 0.5 
3.49 
3.60± 0.3 
3.2 ± 1.7 
26.2 
13.2 ± 1.5 
13.9 ± 1.4 
14.6 ± 2.0 
23.9 ± 3.6 
12.7 ± 1.7 
72.8 ± 14.3 
90.0 ± 10.8 
111.0±13.9 
9.3 ± 2.0 
35.2 ± 1.4 
10.5 ± 0.6 

























9.2 ± 1.7 28.5 
0.8 ± 0.5 54.3 
21.4 ± 3.2 45.3 
10.2 ± 0.8 36.5 
2.4 ± 1.0 68.8 
12.6 ± 0.1 63.8 
8.1 ± 2.0 I 22.2 
Specific [' HJQNB binding values are given in pmol/g protein and are the mean of 4 samples 
± S .E .M. See Table III for description of binding assay. Choline uptake was performed in 
duplicate and is the mean of 2 samples. Velocities of choline uptake are given in nmol/g pro-
tein/4 min. [' H]choline (1 µM) was incubated in 1.9 ml of Krebs po, buffer, pH~ 7.4 at 30° C 
for 4 min. Accumulation of [3H]choline occurring at O oc was subtracted from tota l uptake 
values. Choline acetyltransferase (CAT) activities are given in nmol ACh synthesized/ (mg 
protein)h and are the mean ± S .E.M. of 4 samples. Cholinesterase (ChE) activities are given 
in nmoles ACh hydrolyzed/ (mg protein) min and are the mean of 2 samples. Data are adapted 
from Yamamura et aL.". Value for one monkey. 
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binding reflects the presence of muscarinic cholinergic receptors on axons14• 
This would accord with recent evidence for the existence of presynaptic re-
ceptors for a variety of neurotransmitters in nerve endings and cell bodies of 
the neurons which synthesize the neuro transmitter40- 49 • However lesioning 
studies indicate that QNB binding is almost wholly associated with postsynaptic 
muscarinic receptors18• The septal-hippocampal cholinergic pathway in the 
brain can be destroyed by selective septal lesions36 • These lesions deplete hip-
pocampal acetylcholine and choline acetyltransferase but fail to alter QNB 
binding, which therefore is predominantly post-synaptic18 . 
[3H]-Choline uptake and choline acetyltransferase activity closely parallel 
each other throughout the brain and correlate well with QNB binding in some 
areas. Thus the highest choline uptake and choline acetyltransferase activity 
occur in the head and body of the caudate and in the putamen with values 
several times that of the globus pallidus, just as occurs with QNB binding. 
Similarly the cerebellar cortex and white matter areas contain very low 
amounts of choline acetyltransferase, choline uptake and QNB binding. 
However, there are some striking discrepancies in these correlations. Thus 
within the cerebral hemispheres, the pyriform cortex contains the most choline 
acetyltransferase activity and [3H]-choli:ne uptake, while its QNB binding is 
about the same as for other cerebral regions. Perhaps these data have bearing 
on the relative distribution of muscarinic and nicotinic cholinergic receptors 
throughout the cerebrial cortex. One might speculate that the pyriform cortex 
contains a substantial density of nicotinic receptors not present in other 
cerebral cortical regions. 
Except for the caudate and putamen, the superior colliculi and raphe area 
possess the highest choline acetyltransferase activity in the brain, while QNB 
binding is quite low in the raphe area and moderate in the superior colliculi. By 
contrast, the floor of the fourth ventricle, with one of the lowest QNB binding 
levels, contains substantial choline acetyltransferase activity. Similar regional 
variations in muscarinic receptor binding have been observed for dog brain14. 
As already mentioned, some of the discrepancies between QNB binding 
and other cholinergic markers may relate to relative amounts of nicotinic 
and muscarinic receptors in the brain. However, interpretations must be made 
cautiously. Transmitter synthesis takes place both in cell bodies and nerve 
terminals, while receptor binding presumably is largely associated with sy-
naptic areas as is also the case with high affinity choline uptake. Even if 
choline uptake were to label the nerve terminals of a given synapse and QNB 
binding to involve the associated postsynaptic membrane, the relative surface 
area of nerve ending and postsynaptic element might vary in different brain 
regions. 
Identification of Muscarinic Receptor Binding in vivo 
Although the labelling of the muscarinic receptor with QNB in vitro 
enables one to evaluate many characteristics of the receptor site, it is possible 
that important functional characteristics may be obscured. Thus, changes in 
the number of muscarinic receptor sites under varying physiological and 
pharmacologic conditions may be evanescent and »wash out« during the time 
that one kills the animal and prepares brain homogenates for receptor assay. 
For this reason, the ability to detect cholinergic recepto r binding in vivo would 
be valuable. Perhaps even more important, to perform autoradiographic studies 
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of the receptor under conditions in which morphological relationship of 
neuronal elements are preserved, one would like to label the receptor in vivo. 
Several workers measured the accumulation of cholinergic drugs in mam-
malian brain, but most of the accumulation was rather evenly distributed 
throughout the brain and did not appear io be associated with the muscarinic 
receptor. Because QNB has such a high affinity for the muscarinic receptor, we 
examined its accumulation by various regions and have been able to de-
monstrate that QNB labels selectively the muscarinic cholinergic receptor 
in vivo50 • 
The experimental approach has been rather straightforward. Rats an-
esthetized with ether receive tail vein injections of [3H]-QNB, their brains 
are rapidly dissected and the entire brain region or membrane preparations 
from it analyzed for accumulated radioactivity. In all experiments there is no 
evidence for any metabolism of QNB and all accumulated radioactivity in 
various regions of the brain can be accounted for completely by authentic 
[ 3H]-QNB. 
The principal evidence that QNB labels muscarinic receptors in vivo is 
that the regional distribution of the label after in vivo administration of QNB 
is essentially the same as the regional variation of QNB assayed in vitro 
(Table III). Highest binding occurs in the corpus striatum, with somewhat less 
binding in the cerebral cortex and hippocampus. The hypothalamus and 
medulla-pons contain only about a third of the binding of the corpus striatum 
TABLE III. 





Brain Regions Specifically placeable 
Bound• [3H]QNBh 
--
pmol/g of protein min-1/mg tissue 
Corpus Striatum 478±82 426 
Cerebral Cortex 390±23 348 
Hippocampus 243± 11 278 
Supenior and Inferior 
Colliculi 230±83 -
Midbrain and Pons 150±61 -
Thalamus 137±35 -
Hypothalamus 131 ±38 59 
Medulla Oblongata-
Cervical Spinal Cord 51 ±5 15 
Cerebellar Cortex 34±3 0 
To assay specific binding of ['HJQNB, an a liquot of each brain reg ion was incubated at 25 °c 
with 2 ml of 0.05 M sodium-potassium phosphate buffer (pH= 7.4), conta ining radiolabelled 
QNB. After a 60-min incubation 3 ml of ice-cold buffer w as added and the contents wer<e 
passed throug h a glass filter (GF/BJ positioned over a vacuum. The filters were washed 3 times 
under vacuum with 3 ml of ice-cold buffer. Every determination of binding w as performed in 
triplicate , together with triplicate samples containing u n labelled QNB (0.01 µM) or oxotre-
morine (100 µM) to determine nonspecific [3HJQNB binding . The fil ters were placed in v ia ls 
containing 12 ml of Triton X-100: toluene-phosphor, maintained at 25 oc for 8-12 h a nd the 
radioactivity then assay ed by liquid scintillation spectrometry. Values are the mean ± S.E.M. 
CHOLINERGIC MUSCARINIC RECEPTOR 483 
while QNB accumulation in the cerebellum is the lowest in the. brain, only 
1/6th levels in the corpus striatum. 
Another reason to feel confident that [3H]-QNB in vivo labels the muscari<nic 
receptor is that pretreatment of animals with atropine inhibits QNB binding 
markedly in all areas with the exception of the cerebellum and to a certain 
degree of the medulla-spinal cord (Table, 3). This effect of atropine in preventing 
QNB binding is a very specific one. The nicotinic cholinergic antagonist, me-
camylamine (5 mg/kg), phenobarbital (50 mg/kg) or L-dihydroxyphenylalanine 
(50 mg/kg) fail to prevent [3H]-QNB binding in any areas. Interestingly, QNB 
accumulation in various brain regions is saturable with increasing doses of 
intravenously injected [3H]-QNB. Half-maximal accumulation of [3H]-QNB in 
the corpus striatum is fairly similar to values obtaiined for half-maximal 
saturation in vitro. 
The time-course relationships of QNB accumulation in various brain 
regions are striking (Figure 1). Peak levels ·Occur in all brain regions at 2.5 min, 
the first time poiint measured. In the cerebellum, QNB levels then fall so rapidly 
__ i.____..__ 1___1 _ _ ~-~-~-if-L-ll-1---r!-
o 10 20 30 40 50 60 2 4 24 
\/ min t/h 
Fig. 1. Time course of [' HJQNB accumulation into various regions of rat brain. Rats were 
given 60 µCi of [' HJQNB (4 Ci/ nmol) intravenously via the tail vein in 0.3 ml of saline and 
sacrified after various time intervals. Brain regions were placed in scintillation vials contain-
ing 1 ml of NEN solubilizer (Protosol) and incubated at 37 •c until solubilized. Each point 
represents the mean of at least 3 animals which did not vary more than 10-15°/o. Adapted 
from Yamamura et al.so. 
that by 10 min they are only half of peak values. Thereafter cerebellar QNB 
content declines to value about I /5th of .peak values of 60 min with little 
change for the next 24 hours. In dramatic contrast, the corpus striatum and 
hippocampus evince no reduction in [3H]-QNB levels between 2.5 min and 
4 hours; between 4 and 24 hours levels decline only .about 25°/o·. The fact that 
cerebellar QNB accumulation cannot be prevented by atropine and declines 
much more rapidly than in othe.r regions suggests that QNB accumulation in 
the cerebellum does not involve the cholinergic receptor. The extremely slow 
decline of QNB levels in the cnrpus striatum and hippocampus indicates that 
QNB binds tightly to the muscarinic receptor. 
Autoradiographic Studies 
One of the .aims of obtaining muscanmc receptor binding in vivo is to 
identify the receptor by autoradiographic techniques in the light microscope51 • 
Animals were injected with [3H]-QNB under conditions similar to those 
used for in vivo binding studies and braiins frozen by partial immersion in 
liquid nitrogen, sectioned in a cryostat, »thaw mounted«, developed, fixed , and 
examined using autoradiographic procedu:res essentially similar to those of 
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Anderson and Greenwald52 and Gerlach and McEwen53. After 30 days of 
exposure, a number of interesting features are observed. Areas of the brarin 
containing high densities of autoradiographic grains are the corpus striatum, 
the hippocampus and the cerebral cortex, which also display high levels .of 
QNB binding both in vivo and in vitro (Table IV). As expected, the density of 
TABLE IV. 
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Relative densities were determined by examining the brain region after a 30-d exposure. 
Densities refer to specific binding as they are corrected for blank values obtained by examin-
ing similar regions from a t ropine-pretreated animals. Relative grain densities for cerebral 
cortex and striatum were measured on coronal sections of rat bra in showing Brodal's area 
6 of the cerebral cortex. Data adap ted from Kuhar and Yamamura". 
grains in all brain regions in animals pretreated with atropine is greatly 
lowered. Within the corpus striatum, a high density of grains occurs relatively 
evenly across the entire nucleus and is several times more dense, than the 
distribution over the adjoining globus pallidus and about 20 times greater than 
background grains. 
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Hippocampus has been chosen for more detailed investigation, because its 
cholinergic properties have been characterized extensively biochemically18, 36, 
neurophysiologically and histochemically31,54,55_ About 500/o of hippocampal 
neurons are excited by acetylcholine, an effect which is blocked by atropine54,56 . 
Nerve terminals which histochemically strailll for acetylcholinesterase in the 
electron microscope are distributed throughout regions containing the dendritic 
shafts of the pyramidal cells . Thus it is of interest that within the hippocampus 
a high density of autoradiographic grains is observed over the stratum oriens 
and stratum radiatum, regions containing the apical and basal dendrites of 
the pyramidal cells. Grain density then falls abruptly in the region of the 
alveus, a fiber tract (Figure 2). The stratum moleculare of the dentate gyrus, 
a region containing dendritic shafts of the granule cells, also possesses a high 
grain density which falls abruptly at the ventral boundary of the dentate 
gyrus (Figure 2). The high grain densities around cells in regions described 
Fig. 2. Light autoradiographs of regions of the brain. The grains are shown most clearly in 
(D) (arrow), a higher power micrograph of the striatum. Lower power micrographs are shown 
in (A), (B) and (C) to make the pattern of distribution more observable. Bars represent 25 µm. 
A, section of hippocampus proper showing pyramidal cells and adjacent areas in CAL Note 
the high density of grain over regions on either side of the pyramidal cells, the stratum 
oriens (0) and the stratum radiatum (R), which contain the basal and apical dendrites of the 
pyramidal cells . The density decreases sharply at the boundary of (see arrow pointing along 
the boundary) and over the alveus (A), a fibre tract. B, section of the dentate gyrus showing 
the granule cell layer and the adjacent areas, stratum moleculare (M) and stratum polymorphe 
(P). The stratum moleculare contains the dendritic processes of the granule cells, while the 
stratum polymorphe (this picture shows an area away from the pyramidal cells in CA4), is 
a heterogenous zone containing the axons of the granule cells . Note the much higher density 
of grains in the regions containing the dendritic processes. c, same region as in (B) except 
it is from an atropine-pretreated animal. Note the great reduction in density of grain in the 
stratum moleculare, the dendrite-containing region while there is little or no change in the 
str iatum polymorphe. D, higher magnification of a section of the striatum, a region with a 
similar density of g rains as that of the dendrite-containing regions of the hippocampus. The 
density was relatively uniform across the entire nucleus caudatus-putamen. Data from Kuhar 
and Yamamura" . 
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above contrast with much lower densities around cells in other nuclei such 
as the dorsal midbrain mphe nucleus, medial habenular nucleus, lateral thalamic 
nucleus and periventricular nucleus of the hypothalamus (Table IV). 
Throughout the brain, there is a tendency for autoradiographic grains to 
appear more frequently between rather than over cells, a feature which has 
been verified by grain counts showing more than 4 times as many grains per 
unit area in noncellular as 1in cellular areas. This suggests that most of the 
[ 3H]-QNB binds to dendritic and postsynaptic regions, which are localized to 
areas devoid of cell bodies. In these regions which do not contain cells, one 
presumes that the grains are localized over dendrites containing cho1inergic 
receptors. However it is not possible to visualize such dendrites in the light 
microscope so that one cannot precisely determine which cells have the binding 
sites. 
These preliminary studies demonstrate the feasibility of localizing discrete 
groups of cells that are enriched in muscarinic receptors. 'Such mapping ende-
avors are of importance, because histochemical attempts to study cholinergic 
tracts in the, brain by cholinesterase staining have met with only limited 
success due to the occurrence of considerable cholinesterase· activity in non-
cholinergic systems. The much greater specificity of QNB binding may facilitate 
significant advances in understanding chohlnergic neuronal systems in the 
brain. Studies thus far are only tentative and detailed localization will require 
autoradiography under the electron microscope. 
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SAZETAK 
KolinergiCni muskarinski receptor: Biokemijska i 8vjetlosna autoradiografska 
lokalizacija u mozgu 
H. I. Yamamura, Kwen-Jen Chang*, M. J. Kuhar* i S. H. Snyder* 
Muskarinski kolinergicni antagonist 3-kinuklidinil-benzilat (KNB) vefo se brzo 
ali reversibilno na muskarinski kolinergicni receptor mozga sisavaca i perifernog 
tkiva. Vezanje [3H]-KNB omogucava jednostavnu, osjetljiViu i specificnu metodu 
istrazivanja nacina vezivanja na muskarinski kolinergicni receptor. Inhibicija ve-
zanja [3H]-KNB u homogenatima mozga i Heuma zamorca muskarinskim spojevima 
u korelaciji je s njihovim farmakoloskim ucinkom, dok je afinitet nikotinskih 
agensa i nekolinergicnih spojeva zanemarljiv. Regionalna raspodjela mjesta vezi-
vanja [3H]-KNB u mozgu stakora i majmuna uglavnom se slaze s mjestima vezivanja 
ostalih markiranih kolinergicnih spojeva te ukazuje na to, da je vecina kolinergicnih 
sinapsi u mozgu muskarinske prirode. Nagomilavanje [3H]-KNB u razlicitim dijelo-
488 lt. I. Y A MA MURA ET .4.L. 
vima mozga nakon intravenozne injekcije pretstavlja nacin markiranja muskarinskih 
receptora in vivo. Da bi se dobila predodzba o muskarinskom receptoru, nacinjene su 
autoradiografske studije pod mikroskopom pomocu markiranja receptora in vivo. 
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